Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
14 mai 2024 08h05 HE
|
Palisade Bio, Inc.
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to...
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
27 mars 2024 08h00 HE
|
Palisade Bio, Inc.
– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end – Formation of Clinical...
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference
11 oct. 2023 09h05 HE
|
Palisade Bio, Inc.
Live moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq:...
Palisade Bio Reports Second Quarter 2023 Financial Results
11 août 2023 08h05 HE
|
Palisade Bio, Inc.
– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline – Strong financial position with cash to fund...
Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study
05 juil. 2023 08h45 HE
|
Palisade Bio, Inc.
Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute...
Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14 juin 2023 08h45 HE
|
Palisade Bio, Inc.
Live webcast fireside chat on Thursday, June 22nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies...
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
01 juin 2023 08h45 HE
|
Palisade Bio, Inc.
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...
Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
24 mai 2023 08h45 HE
|
Palisade Bio, Inc.
Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose optimization study with 25% enrollment...
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
06 avr. 2023 09h00 HE
|
Palisade Bio, Inc.
Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...
Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event
09 janv. 2023 08h45 HE
|
Palisade Bio, Inc.
Live video webcast on Tuesday, January 17th at 3:00 PM ET Carlsbad, CA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company...